I keep my business cards in the top drawer of my desk at work. They are in two bulky boxes and take up a lot of space, but I like them there because I can see them every time I pull out a pen. They are a memento of how very often you can’t foresee where an opportunity lies – and therefore to seize each and every one of them. Read more
In the UK, almost half of the public believes that some animal research goes on without an official licence. The situation is similar in the US. This ignorance finds its way to policy makers around the world who dismiss academics and deride science. Clearly, there is a profound imbalance in the knowledge available to scientists and to the rest of society about animal research. Read more
Epitome is a Singapore biotech start-up whose product pipeline is based on engineered tail proteins to tackle bacterial diseases. It wants a slice of the US’s $6bn acne market. Epitome’s founders are seeking raise $10m to build a factory where its cosmetic products can be manufactured. Investors will be rewarded with a seat on its board. Read more
Today we feature Animesh Shukla, a biotechnologist from Meerut Institute of Engineering and Technology in Uttar Pradesh, India who went to Carnegie Mellon University and Indiana University of Bloomington in the USA for PhD. Animesh, who works as a scientist designing ELISA assay kits for Meso Scale Diagnostics now, says planning ahead of time for a postdoctoral career could open up several doors in the land of opportunities. Read more
In this month’s Windback Wednesday series, we’re all about entrepreneurship: what it takes to be one, how to become one and more. But if you’re based in London, it’s not so easy. Although it’s got the brains and research centres to make it a hub, setting up shop in London is the tricky part. In this podcast, I speak to Kit Malthouse, the Deputy Mayor of London for Business and Enterprise, and find out how London is preparing to become the next biotech hub. Read more
In this interview, I speak to Dr. Rob Carlson, a Principal at Biodesic, an engineering and strategic consulting firm in Seattle that provides services to governments and corporations around the globe. At the broadest level, Dr. Carlson is interested in the future role of biology as a human technology. He is the author of the book Biology is Technology: The Promise, Peril, and New Business of Engineering Life, published in 2010 by Harvard University Press; it received the PROSE award for the Best Engineering and Technology Book of 2010 and was named to the Best Books of 2010 lists by writers at both The Economist and ForeignPolicy.com. Carlson is a frequent international speaker and has served as an advisor to such diverse organizations as The Hastings Center, the PICNIC Design Festival, the UN, the OECD, the US Government, and companies ranging in size from start-ups to members of the Fortune 100. Read more
In this podcast, Naturejobs interviews Sterghios Moschos, reader in Industrial Biotechnology and Biochemistry at the University of Westminster in London. We talk about his transition from industry back into academia, and the different attitudes to science that he has experienced. Read more
Recent comments on this blog
African astronomy and how one student broke into the field
From Doctorate to Data Science: A very short guide
Work/life balance: New definitions